provider portal
Wesper Journal
GLP-1 therapies, such as Zepbound (tirzepatide), address obstructive sleep apnea by aiding weight management, thereby reducing airway pressure and improving respiratory health. Wesper's wearable technology enhances treatment by providing continuous monitoring, allowing for timely adjustments to therapy plans. FDA’s Landmark...
Continue reading
In a landmark move, the FDA approved Zepbound (tirzepatide), the first GLP-1-based medication for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity, offering hope beyond traditional CPAP therapy. It works by activating GLP-1 and GIP hormone...
Continue reading
This article explores the relationship between BMI, age, and gender in obstructive sleep apnea (OSA) severity and hypoxic burden. Analyzing two patient cohorts, the study finds that higher BMI is linked to increased apnea-hypopnea index (AHI) and hypoxic burden, though its effect plateaus in severe obesity. Age and male gender emerge as stronger predictors of OSA severity in obese individuals. The findings highlight the potential of GLP-1-induced weight loss to reduce OSA severity but emphasize the need for a multimodal approach, integrating weight management with traditional OSA treatments like CPAP for optimal patient outcomes.
Continue reading